Irreversible electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment?

2.50
Hdl Handle:
http://hdl.handle.net/10541/621264
Title:
Irreversible electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment?
Authors:
De Liguori Carino, N; O'Reilly, D; Siriwardena, A; Valle, Juan W ( 0000-0002-1999-0863 ) ; Radhakrishna, Ganesh; Pihlak, Rille ( 0000-0002-6055-334X ) ; McNamara, Mairéad G ( 0000-0002-2272-3678 )
Abstract:
The incidence of pancreatic ductal adenocarcinoma (PDAC) is rapidly increasing. Up to 30% of patients present with locally advanced disease and therefore are not candidates for surgery. Locally advanced pancreatic cancer (LAPC) is an emerging entity lacking in level III evidence-based recommendations for its treatment. Currently, systemic chemotherapy is the main treatment for LAPC. However, due to lack of response or disease progression, downsizing of the tumour, making it resectable is successful in only a small proportion of patients. Radiotherapy is often advocated to improve local disease control if there is stability following chemotherapy. Recently, Irreversible Electroporation (IRE), a novel non-thermal ablation technique, has been proposed for the treatment of LAPC.
Affiliation:
Regional Hepato-Pancreato-Biliary Unit, Manchester Royal Infirmary, Oxford Road, Manchester, M13 9WL, UK
Citation:
Irreversible electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment? 2018, 44(10): 1486-1493 Eur J Surg Oncol
Journal:
European Journal of Surgical Oncology
Issue Date:
Oct-2018
URI:
http://hdl.handle.net/10541/621264
DOI:
10.1016/j.ejso.2018.07.047
PubMed ID:
30146253
Type:
Article
Language:
en
ISSN:
1532-2157
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorDe Liguori Carino, Nen
dc.contributor.authorO'Reilly, Den
dc.contributor.authorSiriwardena, Aen
dc.contributor.authorValle, Juan Wen
dc.contributor.authorRadhakrishna, Ganeshen
dc.contributor.authorPihlak, Rilleen
dc.contributor.authorMcNamara, Mairéad Gen
dc.date.accessioned2018-09-30T15:35:49Z-
dc.date.available2018-09-30T15:35:49Z-
dc.date.issued2018-10-
dc.identifier.citationIrreversible electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment? 2018, 44(10): 1486-1493 Eur J Surg Oncolen
dc.identifier.issn1532-2157-
dc.identifier.pmid30146253-
dc.identifier.doi10.1016/j.ejso.2018.07.047-
dc.identifier.urihttp://hdl.handle.net/10541/621264-
dc.description.abstractThe incidence of pancreatic ductal adenocarcinoma (PDAC) is rapidly increasing. Up to 30% of patients present with locally advanced disease and therefore are not candidates for surgery. Locally advanced pancreatic cancer (LAPC) is an emerging entity lacking in level III evidence-based recommendations for its treatment. Currently, systemic chemotherapy is the main treatment for LAPC. However, due to lack of response or disease progression, downsizing of the tumour, making it resectable is successful in only a small proportion of patients. Radiotherapy is often advocated to improve local disease control if there is stability following chemotherapy. Recently, Irreversible Electroporation (IRE), a novel non-thermal ablation technique, has been proposed for the treatment of LAPC.en
dc.language.isoenen
dc.rightsArchived with thanks to European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncologyen
dc.titleIrreversible electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment?en
dc.typeArticleen
dc.contributor.departmentRegional Hepato-Pancreato-Biliary Unit, Manchester Royal Infirmary, Oxford Road, Manchester, M13 9WL, UKen
dc.identifier.journalEuropean Journal of Surgical Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.